Free radical mechanisms in schizophrenia and tardive dyskinesia
- PMID: 7708360
- DOI: 10.1016/0149-7634(94)90001-9
Free radical mechanisms in schizophrenia and tardive dyskinesia
Abstract
The present article discusses the distribution of free radical processes in the central nervous system (CNS). Specifically, we discuss the involvement of oxyradicals in the normal metabolism of catecholamine. We also review some proposals related to the possible importance of these compounds in the development of neuropsychiatric and movement disorders such as schizophrenia and neuroleptic-induced tardive dyskinesia (TD), respectively. Clinical studies have shown that antioxidant treatment can attenuate the movement abnormalities observed in TD. Further studies are necessary to evaluate the status of specific scavenging systems in these two disorders. The prophylactic use of antioxidants in patients who are treated with neuroleptics needs also to be considered.
Similar articles
-
Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications.CNS Drugs. 2001;15(4):287-310. doi: 10.2165/00023210-200115040-00004. CNS Drugs. 2001. PMID: 11463134 Review.
-
Free radicals, antioxidant defense systems, and schizophrenia.Prog Neuropsychopharmacol Biol Psychiatry. 2013 Oct 1;46:200-6. doi: 10.1016/j.pnpbp.2013.02.015. Epub 2013 Mar 5. Prog Neuropsychopharmacol Biol Psychiatry. 2013. PMID: 23470289 Review.
-
Tardive dyskinesia: possible involvement of free radicals and treatment with vitamin E.Schizophr Bull. 1999;25(4):731-40. doi: 10.1093/oxfordjournals.schbul.a033414. Schizophr Bull. 1999. PMID: 10667743 Review.
-
Vitamin E in the treatment of tardive dyskinesia: the possible involvement of free radical mechanisms.Schizophr Bull. 1988;14(2):291-6. doi: 10.1093/schbul/14.2.291. Schizophr Bull. 1988. PMID: 2904696 Clinical Trial.
-
The current status of tardive dyskinesia.Aust N Z J Psychiatry. 2000 Jun;34(3):355-69. doi: 10.1080/j.1440-1614.2000.00737.x. Aust N Z J Psychiatry. 2000. PMID: 10881961 Review.
Cited by
-
Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications.CNS Drugs. 2001;15(4):287-310. doi: 10.2165/00023210-200115040-00004. CNS Drugs. 2001. PMID: 11463134 Review.
-
Reactive oxygen species and reactive nitrogen species: relevance to cyto(neuro)toxic events and neurologic disorders. An overview.Neurotox Res. 2000 Feb;1(3):197-233. doi: 10.1007/BF03033290. Neurotox Res. 2000. PMID: 12835102
-
Divergent long-term consequences of chronic treatment with haloperidol, risperidone, and bromocriptine on traumatic brain injury-induced cognitive deficits.J Neurotrauma. 2015 Apr 15;32(8):590-7. doi: 10.1089/neu.2014.3711. Epub 2015 Jan 8. J Neurotrauma. 2015. PMID: 25275833 Free PMC article.
-
Jobelyn® improves motor dysfunctions induced by haloperidol in mice via neuroprotective mechanisms relating to modulation of cAMP response-element binding protein and mitogen-activated protein kinase.Metab Brain Dis. 2023 Oct;38(7):2269-2280. doi: 10.1007/s11011-023-01253-z. Epub 2023 Jun 22. Metab Brain Dis. 2023. PMID: 37347426
-
The neurotoxicity of glutamate, dopamine, iron and reactive oxygen species: functional interrelationships in health and disease: a review-discussion.Neurotox Res. 1999 Sep;1(1):27-39. doi: 10.1007/BF03033337. Neurotox Res. 1999. PMID: 12835112
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical